MCID: CHL065
MIFTS: 62

Cholangiocarcinoma malady

Categories: Genetic diseases, Liver diseases, Cancer diseases, Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Cholangiocarcinoma

About this section
Sources:
32LifeMap Discovery®, 10Disease Ontology, 22GeneTests, 47Novoseek, 12DISEASES, 51Orphanet, 36MeSH, 24GTR, 65UMLS, 27ICD10, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Cholangiocarcinoma:

Name: Cholangiocarcinoma 32 10 22 47 12 51 36 24 65
Adult Primary Cholangiocellular Carcinoma 10 65
Adult Primary Cholangiocarcinoma 10
Bile Duct Carcinoma 65
 
Bile Duct Cancer 51
Cholangiosarcoma 10
Cca, Icca, Icc 22
Cca 51

Characteristics:

Orphanet epidemiological data:

51
cholangiocarcinoma:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult

Classifications:



External Ids:

Disease Ontology10 DOID:4947
ICD1027 C22.1
MeSH36 D018281
NCIt42 C4436, C8265
SNOMED-CT59 312104005, 70179006
Orphanet51 70567
ICD10 via Orphanet28 C24.8, C24.9, C24.0 C22.1, more
MESH via Orphanet37 D001650, D018281
UMLS via Orphanet66 C0206698, C0740277
UMLS65 C0206698, C0280725

Summaries for Cholangiocarcinoma

About this section
Wikipedia:68 Cholangiocarcinoma or bile duct cancer is a form of cancer that is composed of mutated epithelial cells... more...

MalaCards based summary: Cholangiocarcinoma, also known as adult primary cholangiocellular carcinoma, is related to bile duct carcinoma and ovarian cancer, and has symptoms including abnormality of urine homeostasis, biliary tract neoplasm and pruritus. An important gene associated with Cholangiocarcinoma is PTPN3 (Protein Tyrosine Phosphatase, Non-Receptor Type 3), and among its related pathways are EGFR Signaling Pathway and a6b1 and a6b4 Integrin signaling. Affiliated tissues include liver, breast and lung, and related mouse phenotypes are endocrine/exocrine gland and normal.

Disease Ontology:10 A bile duct adenocarcinoma that has material basis in bile duct epithelial cells.

Related Diseases for Cholangiocarcinoma

About this section

Diseases related to Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 951)
idRelated DiseaseScoreTop Affiliating Genes
1bile duct carcinoma30.8AFP, KRT19, KRT7, MUC1, MUC5AC
2ovarian cancer30.7CDX2, MUC1
3clear cell basal cell carcinoma30.4CDH1, KRT19
4papillary carcinoma30.4CDH1, ERBB2, MUC1
5lung cancer30.3CDH1, ERBB2, KRT19, MCL1, MET, MMP7
6liver cirrhosis30.2KRT19, MUC4, MUC5AC
7hepatocellular adenoma30.2CDH1, KRT19, PTGS2, VEGFC
8ulnar neuropathy30.1CDX2, MMP7, PTGS2
9paraplegia30.1CDX2, KRT7, MUC5AC
10breast cancer29.9CDH1, ERBB2, KRT19, KRT8, MET, MUC1
11pancreatic ductal adenocarcinoma29.9CDH1, MUC1, MUC4, MUC5AC, SMAD4
12hepatocellular carcinoma29.9AFP, CDH1, GPC3, KRT19, KRT7, MCL1
13colorectal cancer28.6CDH1, CDX2, ERBB2, KRT19, MCL1, MET
14intrahepatic cholangiocarcinoma12.7
15mucinous intrahepatic cholangiocarcinoma12.4
16signet ring cell intrahepatic cholangiocarcinoma12.3
17sarcomatous intrahepatic cholangiocarcinoma12.3
18contractural arachnodactyly, congenital12.0
19klatskin's tumor11.8
20breast ductal adenoma10.6CDH1, ERBB2
21situs inversus10.6ERBB2, MUC1
22thymus adenocarcinoma10.6ERBB2, MUC1, MUC4
23breast granular cell tumor10.6CDH1, ERBB2, MUC1
24nonsyndromic hereditary sensorineural hearing loss10.6AFP, ERBB2
25venous hemangioma10.6MUC1, MUC4
26nasal cavity squamous cell carcinoma10.6CDH1, ERBB2
27benign struma ovarii10.5AFP, KRT19
28intramuscular hemangioma10.5MUC1, MUC5AC
29estrogen-receptor positive breast cancer10.5CDH1, ERBB2, MUC1, PTGS2
30ovarian cystic teratoma10.5AFP, MUC1
31proctitis10.5CDH1, ERBB2, PTGS2
32appendix lymphoma10.5CDH1, KRT7, MUC1
33lymphangitis10.5MUC1, MUC4, MUC5AC
34childhood choriocarcinoma of the ovary10.5ERBB2, KRT7
35hereditary breast ovarian cancer10.5AFP, GPC3
36pagod syndrome10.5ERBB2, KRT7, MUC1
37immunodeficiency 27b, mycobacteriosis, ad10.5MMP7, PTGS2
38breast secretory carcinoma10.5KRT19, KRT7
39hypothalamic disease10.5AFP, CDH1, ERBB2
40simple chronic conjunctivitis10.5MUC1, MUC4, MUC5AC
41eye carcinoma in situ10.5CDH1, ERBB2, KRT19, MET
42vibratory urticaria10.5KRT19, MET, PTGS2
43biliary tract neoplasm10.5CDH1, KRT7, PTGS2
44spondylitis10.5ERBB2, KRT7
45adult spinal cord ependymoma10.5ERBB2, KRT8
46polyp of corpus uteri10.5MET, MMP7, SMAD4
47contact lens corneal edema10.5KRT19, KRT8
48asthenopia10.5MUC1, MUC4, MUC5AC
49ovary epithelial cancer10.5CDH1, ERBB2, KRT7
50ovarian wilms' cancer10.5CDH1, ERBB2, KRT7

Graphical network of the top 20 diseases related to Cholangiocarcinoma:



Diseases related to cholangiocarcinoma

Symptoms for Cholangiocarcinoma

About this section

Symptoms:

 51 (show all 9)
  • hepatitis/icterus/cholestasis
  • abnormal colour of the urine/cholic/dark urines
  • extrahepatic biliary tract/gallbladder neoplasm/tumor/carcinoma/cancer
  • pruritus/itching
  • asthenia/fatigue/weakness
  • acute abdominal pain/colic
  • anorexia
  • weight loss/loss of appetite/break in weight curve/general health alteration
  • fever/chilling

HPO human phenotypes related to Cholangiocarcinoma:

(show all 8)
id Description Frequency HPO Source Accession
1 abnormality of urine homeostasis hallmark (90%) HP:0003110
2 biliary tract neoplasm hallmark (90%) HP:0100574
3 pruritus typical (50%) HP:0000989
4 weight loss occasional (7.5%) HP:0001824
5 abdominal pain occasional (7.5%) HP:0002027
6 anorexia occasional (7.5%) HP:0002039
7 abnormality of temperature regulation occasional (7.5%) HP:0004370
8 cholangiocarcinoma HP:0030153

Drugs & Therapeutics for Cholangiocarcinoma

About this section

Drugs for Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 189)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Midazolamapproved, illicitPhase 463559467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
Dormicum
 
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam Hydrochloride
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
2
EtomidateapprovedPhase 45733125-97-236339, 667484
Synonyms:
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-Etomidate
(+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-etomidate
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
(d)-Etomidate
1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester
1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester
15301-65-2
1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
33125-97-2
AC-5898
AC1L1VLF
AC1Q34BV
AC1Q64LP
AKOS000548952
Absele
Amidate
Amidate (TN)
Amidate (pharmaceutical)
Amidate, Etomidate
BAS 01947657
BRN 0665833
C07522
C14H16N2O2
CHEBI:129025
CHEMBL23731
CID36339
CPD000010931
D-Etomidate
D005045
D00548
 
DB00292
EINECS 251-385-9
Ethnor
Ethomidate
Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
Etomidate
Etomidate (USAN/INN)
Etomidate [USAN:BAN:INN]
Etomidato
Etomidato [INN-Spanish]
Etomidatum
Etomidatum [INN-Latin]
Etomidic acid
HMS1571A04
HMS1612G10
HMS2093P17
Hypnomidate
LS-78232
MLS000034952
MLS001240191
MolPort-000-917-569
Prestwick0_001041
Prestwick1_001041
Prestwick2_001041
R 16659
R 26490
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
R-26490
R26490
Radenarcon
Radenarkon
S1329_Selleck
SAM002548930
SBB066197
SMR000010931
SPBio_002901
UNII-Z22628B598
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate
3
MeperidineapprovedPhase 46557-42-14058
Synonyms:
1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]
1-Methyl-4-phenylisonipecotic acid, ethyl ester
1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester
4-Carbethoxy-1-methyl-4-phenylpiperidine
4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
50-13-5 (hydrochloride)
57-42-1
610593_ALDRICH
610593_FLUKA
AC1L1HBJ
C07128
CHEBI:122528
CHEMBL607
CID4058
D008614
D08343
DB00454
DEA No. 9230
Demarol
Demerol
DivK1c_000983
Dolcontral
Dolosal
Dolsin
EINECS 200-329-1
Ethyl 1-methyl-4-phenylisonipecotate
Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
HSDB 3116
IDI1_000983
Isonipecain
Isonipecaine
Isonipecaïne
Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester
KBio1_000983
L000908
LS-85121
 
Lidol
Lydol
Meperidine
Meperidine Hydrochloride
Meperidine hydrochloride
Meperidine solution
Meperidol
Methyl phenylpiperidine carbonic acid ethyl ester
MolPort-001-785-564
N-Methyl-4-phenyl-4-carbethoxypiperidine
NINDS_000983
Nemerol
Operidine EPJ I
Operidine EPJ-I
Pethanol
Pethidin
Pethidine
Pethidine (INN)
Pethidine DBL
Pethidine DBL (TN)
Pethidine dbl
Pethidine hydrochloride
Pethidineter
Pethidinum
Pethidinum [INN-Latin]
Petidina
Petidina [INN-Spanish]
Petydyna
Petydyna [Polish]
Phetidine
Piperosal
Pipersal
Péthidine
Sauteralgyl
Spasmedal
Spasmodolin
UNII-9E338QE28F
YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI)
meperidine
4
SevofluraneapprovedPhase 442928523-86-65206
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
BRN 2041023
Bax 3084
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
LS-67851
MR6S4
 
MR_6S4
MolPort-001-775-746
NCGC00167421-01
PC4681
Sevofluran
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
UNII-38LVP0K73A
Ultane
Ultane (TN)
ZINC01530810
fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
sevoflurane
5
DesfluraneapprovedPhase 412557041-67-542113
Synonyms:
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane
2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
57041-67-5
AC1L274J
AC1Q4ICY
C07519
C3H2F6O
CHEBI:4445
CHEMBL1200733
CID42113
D00546
DB01189
DESFLURANE
Desflurane
 
Desflurane (JAN/USP/INN)
Desflurane [USAN:INN]
Desflurano
Desflurano [INN-Spanish]
Desfluranum
Desfluranum [INN-Latin]
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
I 653
I-653
I653
LS-65505
MolPort-001-776-387
PC6781E
Suprane
Suprane (TN)
UNII-CRS35BZ94Q
difluoromethyl 1,2,2,2-tetrafluoroethyl ether
r-e 236ea1
6Psychotropic DrugsPhase 45501
7Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018510
8Neurotransmitter AgentsPhase 414795
9Tranquilizing AgentsPhase 43597
10
BismuthPhase 4, Phase 31037440-69-916682734, 105143
Synonyms:
17034_FLUKA
24267-48-9
25243-76-9
264008_ALDRICH
265462_ALDRICH
265470_ALDRICH
452386_ALDRICH
556130_ALDRICH
7440-69-9
83Bi
95372_ALDRICH
95372_FLUKA
95375_FLUKA
AC1NSDYX
AC1O4PN8
AR-1I0647
BISMUTH, 99.95%
 
BISMUTH, 99.999%
Bi
Bismut
Bismuth standard for AAS
Bismuth standard for ICP
Bismuth(III) nitrate solution
Bismuth, elemental
Bismuth-209
C15471
CHEBI:33301
CID5359367
EINECS 231-177-4
HSDB 2078
LS-44708
LTBB002773
MolPort-003-925-759
Wismut
bismuth
bismuto
11Anesthetics, IntravenousPhase 41943
12AnalgesicsPhase 4, Phase 1, Phase 29358
13NarcoticsPhase 42709
14Analgesics, OpioidPhase 42304
15Central Nervous System DepressantsPhase 410016
16Anti-Anxiety AgentsPhase 41529
17Anesthetics, GeneralPhase 42274
18GABA ModulatorsPhase 4657
19AnestheticsPhase 47385
20Hypnotics and SedativesPhase 42032
21Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13572
22Platelet Aggregation InhibitorsPhase 41935
23Anesthetics, InhalationPhase 4511
24
BilirubinPhase 4103635-65-45280352
Synonyms:
(4Z,15Z)-Bilirubin IXa
(Z,Z)-Bilirubin IXa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
 
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
Bilirubin
Bilirubin IX-alpha
Cholerythrin
Hematoidin
25Omega 3 Fatty AcidNutraceuticalPhase 4912
26
CisplatinapprovedPhase 3, Phase 1, Phase 2254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
27
GemcitabineapprovedPhase 3, Phase 1, Phase 2, Phase 0188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
28
FluorouracilapprovedPhase 3, Phase 2, Phase 1168451-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
29
Capecitabineapproved, investigationalPhase 3, Phase 1, Phase 21220154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
30
TrioxsalenapprovedPhase 3, Phase 2403902-71-45585
Synonyms:
2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
Trimethylpsoralen
Trioxisaleno
 
Trioxsalen
Trioxysalen
Trioxysalene
Trioxysalenum
Trisoralen
trimethylpsoralen
trioxysalen
trisoralen
31
Ursodeoxycholic acidapproved, investigationalPhase 2, Phase 378128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
ISO-URSODEOXYCHOLIC ACID
 
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol Tablets, 250 mg
Ursodiol Tablets, 500 mg
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
32
leucovorinapprovedPhase 3, Phase 2, Phase 19521492-18-854575
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid-SF
Fusilev
 
L-Folinic acid
L-leucovorin
Leucal
Leucovorin
Leucovorin Calcium
Leucovorin calcium
Leucovorin folinic acid
Leucovorin sodium
Leukovorin
Levofolene
Levofolinic acid
Levoleucovorin
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
Wellcovorin
33
Oxaliplatinapproved, investigationalPhase 3, Phase 1, Phase 2, Phase 0132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
34
SuccinylcholineapprovedPhase 3, Phase 1141306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
35
Folic Acidapproved, nutraceuticalPhase 3, Phase 2, Phase 1292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
36AntiemeticsPhase 3, Phase 2, Phase 1, Phase 03213
37MicronutrientsPhase 3, Phase 23901
38Vitamin B ComplexPhase 3, Phase 2, Phase 12847
39VitaminsPhase 3, Phase 23857
40Trace ElementsPhase 3, Phase 23900
41Protective AgentsPhase 3, Phase 1, Phase 25651
42HematoporphyrinsPhase 310
43LevoleucovorinPhase 3, Phase 1, Phase 2676
44EtherPhase 3, Phase 252
45Antimetabolites, AntineoplasticPhase 3, Phase 1, Phase 2, Phase 05770
46Antiviral AgentsPhase 3, Phase 1, Phase 2, Phase 08071
47Gastrointestinal AgentsPhase 2, Phase 3, Phase 1, Phase 06401
48Immunosuppressive AgentsPhase 3, Phase 1, Phase 2, Phase 010422
49AntimetabolitesPhase 3, Phase 1, Phase 2, Phase 09454
50Anti-Infective AgentsPhase 3, Phase 1, Phase 2, Phase 017220

Interventional clinical trials:

(show top 50)    (show all 260)
idNameStatusNCT IDPhase
1Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar CholangiocarcinomaCompletedNCT00721175Phase 4
2Etomidate vs. Midazolam for Sedation During ERCPCompletedNCT02027311Phase 4
3Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological TumorsCompletedNCT00168987Phase 4
4Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic StentRecruitingNCT00746538Phase 4
5Preoperative Biliary Drainage for Resectable Hilar CholangiocarcinomaRecruitingNCT00797121Phase 4
6Anesthetic Agents and Acute Kidney Injury After Liver Resection SurgeryRecruitingNCT02174575Phase 4
7Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary ObstructionRecruitingNCT02166970Phase 4
8Lipidomics, Proteomics, Micro RNAs and Volatile Organic CompoundsRecruitingNCT02531607Phase 4
9Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar StrictureRecruitingNCT01125865Phase 4
10Stereotactic Body Radiotherapy for Liver TumorsActive, not recruitingNCT01347333Phase 4
11Early Oral Versus Enteral Nutrition After PancreatoduodenectomyActive, not recruitingNCT01642875Phase 4
12S-1 and Photodynamic Therapy in CholangiocarcinomaCompletedNCT00869635Phase 3
13Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract TumorsCompletedNCT00262769Phase 3
14Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by SurgeryCompletedNCT00513539Phase 3
15Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract CancerCompletedNCT00363584Phase 3
16Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related SymptomsCompletedNCT01640522Phase 3
17Trial of High-dose Urso in Primary Sclerosing CholangitisCompletedNCT00059202Phase 2, Phase 3
18Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar CholangiocarcinomaRecruitingNCT02108145Phase 2, Phase 3
19Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)RecruitingNCT02082522Phase 3
20Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable CholangiocarcinomaRecruitingNCT01739465Phase 2, Phase 3
21Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic CholangiocarcinomaRecruitingNCT02548195Phase 3
22Photodynamic Therapy (PDT) for Palliation of CholangiocarcinomaRecruitingNCT01755013Phase 2, Phase 3
23Chemo Alone or in Combination With Radiation in Unresectable CholangiocarcinomaRecruitingNCT02773485Phase 3
24RFA RCT for Pancreatic or Bile Duct CancerRecruitingNCT02166190Phase 3
25Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract CancerRecruitingNCT02170090Phase 3
26IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary ObstructionRecruitingNCT02001779Phase 3
27Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by SurgeryRecruitingNCT02200042Phase 3
28Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct StricturesRecruitingNCT01721174Phase 2, Phase 3
29Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar StricturesRecruitingNCT00653978Phase 3
30Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract CancersRecruitingNCT01926236Phase 3
31Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract CarcinomaRecruitingNCT01470443Phase 3
32Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by SurgeryRecruitingNCT01313377Phase 3
33Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With CholangiocarcinomaActive, not recruitingNCT02482454Phase 2, Phase 3
34Safety and Efficiency of Photodynamic Therapy for Blie Duct CarcinomaSuspendedNCT01859169Phase 2, Phase 3
35Photodynamic Therapy (PDT) Trial for Palliation of CholangiocarcinomaTerminatedNCT00907413Phase 3
36Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV CholangiocarcinomasTerminatedNCT00540735Phase 3
37XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary TumorsTerminatedNCT00090025Phase 3
38Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By SurgeryWithdrawnNCT00253617Phase 3
39Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar ObstructionWithdrawnNCT01622803Phase 3
40Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced CholangiocarcinomaCompletedNCT00350961Phase 1, Phase 2
41Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder CancerCompletedNCT00660140Phase 2
42Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for CholangiocarcinomaCompletedNCT01253148Phase 2
43S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT00238212Phase 2
44A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary CancersCompletedNCT00660699Phase 2
45Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT01093222Phase 2
46Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the GallbladderCompletedNCT00084942Phase 2
47S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT00033540Phase 2
48Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.CompletedNCT01073839Phase 1, Phase 2
49Oxaliplatin and Capecitabine in Patients With Unresectable CholangiocarcinomaCompletedNCT00338988Phase 2
50Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver MetastasesCompletedNCT01290536Phase 2

Search NIH Clinical Center for Cholangiocarcinoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cholangiocarcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cholangiocarcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Cholangiocarcinoma:
Tumor infiltrating lymphocytes, PMIDs: 24329789, 19342963, 23904171, 21498393, 22996367, 19304471, 22555974, 15800326, 23650429, 21325070, 24218514, 8170938, 12242449


Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Cholangiocarcinoma

About this section

Genetic tests related to Cholangiocarcinoma:

id Genetic test Affiliating Genes
1 Cholangiocarcinoma22 PTPN3

Anatomical Context for Cholangiocarcinoma

About this section

MalaCards organs/tissues related to Cholangiocarcinoma:

33
Liver, Breast, Lung, Small intestine, T cells, Brain, Kidney

Animal Models for Cholangiocarcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Cholangiocarcinoma:

38 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053799.6AFP, CDH1, CDX2, ERBB2, KRT19, MCL1
2MP:00028739.6CDH1, CDX2, ERBB2, KRT19, MCL1, MET
3MP:00053809.4CDH1, CDX2, ERBB2, GPC3, KRT19, KRT8
4MP:00020069.4AFP, ASPH, CDH1, CDX2, ERBB2, KRT19
5MP:00053899.2AFP, ASPH, CDH1, CDX2, ERBB2, GPC3
6MP:00053849.0CDH1, CDX2, ERBB2, GPC3, KRT19, KRT7
7MP:00053818.8ASPH, CDH1, CDX2, ERBB2, GPC3, KRT19
8MP:00053878.8CDH1, GPC3, KRT8, MCL1, MET, MMP7
9MP:00053788.8ASPH, CDH1, CDX2, ERBB2, GPC3, KRT19
10MP:00053858.7ASPH, CDH1, CDX2, ERBB2, GPC3, KRT19
11MP:00107688.5AFP, ASPH, CDH1, CDX2, ERBB2, GPC3
12MP:00053768.4AFP, ASPH, CDH1, CDX2, ERBB2, GPC3

Publications for Cholangiocarcinoma

About this section

Articles related to Cholangiocarcinoma:

(show top 50)    (show all 1616)
idTitleAuthorsYear
1
Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. (25422311)
2015
2
Type 2 segmental glomangioma - Case report. (26312686)
2015
3
Dystrophic Epidermolysis Bullosa Associated with Amniotic Band Syndrome. (24383893)
2014
4
Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy. (24664294)
2014
5
An updated meta-analysis of transforming growth factor-I^1 gene: three polymorphisms with gastric cancer. (24254308)
2013
6
Forkhead box O1 (FOXO1) in pregnant human myometrial cells: a role as a pro-inflammatory mediator in human parturition. (23778262)
2013
7
Cardiac sarcoidosis mimicking arrhythmogenic right ventricular dysplasia with high defibrillation threshold requiring subcutaneous shocking coil implantation. (21982156)
2012
8
Natural progression of dysplasia in adult recurrent respiratory papillomatosis. (21493426)
2011
9
Identification of K-RAS mutations in colorectal cancer patients in Israel]. (21678640)
2011
10
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. (21556038)
2011
11
Associated symptoms of kawasaki disease. (21860641)
2011
12
Chronic monolateral otomycosis in a dog caused by Aspergillus ochraceus. (20409075)
2010
13
OGG1 is a novel prognostic indicator in acute myeloid leukaemia. (20023702)
2010
14
Oral mucous squamous cell carcinoma-an anticipated consequence of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). (20304522)
2010
15
Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism. (20079455)
2010
16
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. (20019066)
2010
17
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. (20888065)
2010
18
Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. (18676015)
2009
19
STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. (19019891)
2009
20
Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. (19698996)
2009
21
Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. (18382884)
2008
22
Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. (19337453)
2008
23
Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. (17496236)
2007
24
The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. (15994236)
2005
25
The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies. (16238533)
2005
26
Toward better antibiotics: crystallographic studies of a novel class of DD-peptidase/beta-lactamase inhibitors. (15170342)
2004
27
Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations. (15159322)
2004
28
N-acetylcysteine inhibits peroxynitrite-mediated damage in oleic acid-induced lung injury. (15477121)
2004
29
Human dirofilariasis of the buccal mucosa: a case report. (12653245)
2003
30
Cytomorphology of verrucous carcinoma of the cervix. A case report. (14674078)
2003
31
Basic residues within the Kruppel zinc finger DNA binding domains are the critical nuclear localization determinants of EKLF/KLF-1. (11844803)
2002
32
Axillary lymphadenopathy as the primary presentation of primary peritoneal carcinoma. (12592068)
2002
33
Response to resistive strengthening exercise training in humans with neuromuscular disease. (12409817)
2002
34
Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. (12070140)
2002
35
The pathogenesis of Crohn's disease in the 21st century. (12555995)
2002
36
Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. (11706006)
2002
37
Dietary protective and risk factors for esophageal and stomach cancers in a low-epidemic area for stomach cancer in Jiangsu Province, China: comparison with those in a high-epidemic area. (11714439)
2001
38
ERO1-L, a human protein that favors disulfide bond formation in the endoplasmic reticulum. (10671517)
2000
39
Prion protein glycotype analysis in familial and sporadic Creutzfeldt-Jakob disease patients. (10483920)
1999
40
Preferential binding of lysozyme to elastic fibres in pulmonary emphysema. (9659355)
1998
41
Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption. (9762356)
1998
42
Mutations in the FVIII gene in seven families with mild haemophilia A. (9029040)
1997
43
Crx, a novel Otx-like paired-homeodomain protein, binds to and transactivates photoreceptor cell-specific genes. (9390516)
1997
44
Evaluation of the effectiveness of antihypertensive therapy. Is the trough-peak ratio the determining factor?]. (8686181)
1996
45
Expression of membrane-type matrix metalloproteinase (MT-MMP) and activation of MMP-2 in lung cancer]. (7630026)
1995
46
UMOD-Associated Kidney Disease (20301530)
1993
47
Severe visual loss associated with retinal telangiectasis and facioscapulohumeral muscular dystrophy. (1505769)
1992
48
Lymphedema tarda. (946512)
1976
49
A method for reducing the incidence of infusion phlebitis. (1154216)
1975
50

Variations for Cholangiocarcinoma

About this section

Cosmic variations for Cholangiocarcinoma:

7 (show top 50)    (show all 553)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
2COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
3COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
4COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
5COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
6COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
7COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
8COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
9COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
10COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
11COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
12COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
13COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
14COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
15COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
16COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
17COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
18COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
19COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
20COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
21COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
22COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
23COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
24COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
25COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
26COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
27COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
28COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
29COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
30COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
31COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
32COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
33COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
34COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
35COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
36COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
37COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
38COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
39COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
40COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
41COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
42COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
43COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
44COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
45COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
46COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
47COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
48COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
49COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1
50COSM521KRASbiliary tract,bile duct,carcinoma,adenocarcinoma1

Expression for genes affiliated with Cholangiocarcinoma

About this section
Search GEO for disease gene expression data for Cholangiocarcinoma.

Pathways for genes affiliated with Cholangiocarcinoma

About this section

GO Terms for genes affiliated with Cholangiocarcinoma

About this section

Cellular components related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1costamereGO:004303410.4KRT19, KRT8
2keratin filamentGO:004509510.3KRT7, KRT8
3Golgi lumenGO:000579610.1GPC3, MUC1, MUC4
4cell peripheryGO:007194410.0KRT19, KRT8
5intermediate filamentGO:00058829.8KRT19, KRT8

Biological processes related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1O-glycan processingGO:001626610.1MUC1, MUC4, MUC5AC
2negative regulation of cell proliferationGO:00082859.8ASPH, PTGS2, SMAD4, VEGFC

Sources for Cholangiocarcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet